Myd88 |
|
Vaxjo ID |
219 |
|
Vaccine Adjuvant Name |
Myd88 |
|
Adjuvant VO ID |
VO_0005270
|
|
Stage of Development |
Research |
|
Components |
Myeloid differentiation factor 88 (Myd88), a ubiquitous Toll-like receptor adaptor molecule, has been reported to play important roles in B cell responses to infections and vaccination. The present study evaluated the effects of genetic adjuvanting with Myd88 on the immune responses to a plasmid DNA rabies vaccine. |
|
Preparation |
Constructed as plasmids encoding rabies glycoprotein alone (pIRES-Rgp) or with a fragment of the Myd88 gene (pIRES-Rgp-Myd). |
|
Dosage |
Administered intramuscularly or intradermally on days 0, 7, and 21 in Swiss albino mice. Specific dosage not mentioned. |
|
Function |
Genetic adjuvanting with Myd88 enhanced the RVNA responses and protective efficacy of a plasmid DNA rabies vaccine. This strategy might be useful for rabies vaccination of canines in the field, and needs further evaluation |
| Related Vaccine(s) |
|
| References |
Ullas et al., 2014: Ullas PT, Desai A, Madhusudana SN. Immunogenicity and efficacy of a plasmid DNA rabies vaccine incorporating Myd88 as a genetic adjuvant. Clinical and experimental vaccine research. 2014; 3(2); 202-211. [PubMed: 25003094].
|
